Table 2.
Immunosuppressant drugs: exposure and response
| Drug | N | Total exposure (days) | CR | PR | NR | Remissionb with drug (%) | Number of adverse events (%) |
|---|---|---|---|---|---|---|---|
| Alkylating agents | 9 | 90±42 | 2 | 4 | 3 | 67 | 2 (22) |
| Cyclosporine | 15 | 961±1,054 | 6 | 7 | 2 | 87 | 4 (27) |
| Tacrolimus | 13 | 612±363 | 6 | 5 | 2 | 85 | 5 (38) |
| Mycophenolate mofetil | 18 | 486±305 | 4 | 8 | 6 | 67 | 2 (11) |
| Rituximab | 4 | 1–2 (doses) | 1 | 2 | 1 | 75 | 0 |
| Nonea | 1 | – | – | 1 | – | 100 | 0 |
CR, complete remission (Up/c <0.2 mg/mg or urine dipstick negative or trace); PR, partial remission (Up/c decreased by >50 % and <2.0 mg/mg or urine dipstick 1+ to 2+); NR, no response (Up/c >2.0 mg/mg or urine dipstick 3+ to 4+)
Data are presented as the mean ± SD where appropriate
a
No additional immunosuppressant therapy: angiotensin-converting enzyme inhibitor (ACE-I) treatment only
b
CR or PR at the end of treatment course with individual drug